The product (CD4-immunoglobulin G2) is a tetravalent CD4-immunoglobulin fusion protein that broadly neutralizes primary HIV-1 isolates.
>99% by SDS-Page and HPLC analysis
<0.001 EU per 1 μg of the peptide by the LAL method
Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications.
Examples of Clinical Use:
Acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications
Mechanism of action:
PRO 542 binds to the viral surface glycoprotein gp120 and blocks attachment and entry of virus into CD4(+) cells.Unlike currently approved therapies that block viral replication in cells already infected with HIV, PRO 542 is an antibody-like molecule that is designed to target and neutralize the virus in the bloodstream. Single doses of PRO 542 reduced concentrations of the human immunodeficiency (HIV) in the blood by 60% to 80% in a target population of highly treatment-experienced patients with PRO 542-sensitive virus.
The CD4-immunoglobulin G2 protein, also known as the CD4-IgG2, is a potent player in human health and disease. This protein holds great promise in several areas of medicine and is currently under intense study for its potential therapeutic applications.
Background of CD4-IgG2
The CD4-IgG2 is a product of our understanding of the biochemical intricacies of the human body. This protein is designed by scientists to mimic the CD4 receptor, a cell surface protein primarily found on helper T cells. The invention of CD4-IgG2 was sparked by the understanding of the role of CD4 receptors in HIV infection, where the HIV virus attaches itself to these receptors to gain entry into host cells.
The gene locus for CD4-IgG2 is an engineered sequence that got combined to form a bifunctional protein: one part from the CD4 protein and the other part from the immunoglobulin G2 (IgG2) protein. The overall result is a protein that can both bind to the HIV virus (through the CD4 part) and to immune cells (through the IgG2 part), enhancing immune response against the virus.
CD4-IgG2 Protein Function
The design of the CD4-IgG2 integrates the functions of its parental proteins. It mainly works by binding to the HIV virus and preventing it from infecting host cells. This action is accomplished by the CD4 portion, which fits snugly into the groove on the HIV virus designed for CD4 receptors. After capturing an HIV virus, the IgG2 part of CD4-IgG2 can then signal for immune cells to destroy the captured virus.
CD4-IgG2 protein-related signaling pathways
The CD4-IgG2, due to its powerful binding ability to HIV and other similar viruses, triggers a number of signaling pathways. Remarkably, the interaction with immune cells is mediated through the Fc region of the protein, which is identifiable by Fc receptor-bearing immune cells such as natural killer cells and macrophages. The binding of the Fc region to these immune cells triggers a cascade of events that lead to the destruction of the bound virus.
Disease Implications and CD4-IgG2's Role
Given its potent anti-viral action, CD4-IgG2 holds potential promise in the management of HIV infections and other similar diseases. Its mechanism of action is different from most retroviral drugs, which usually target the virus's enzymes. This unique mechanism contributes to CD4-IgG2's potential as a drug candidate and could be crucial in combating drug-resistant virus strains.
The Application of CD4-IgG2 Protein in Medicine
In the realm of medicine, the CD4-IgG2 is a beacon of hope in the treatment of HIV infections. It has shown to be effective in vitro and in primate models of HIV/AIDS. The most important aspect is that it can target the virus without harming the host cells and can potentially activate the immune system to destroy the virus.
List of Drug Candidates related to CD4-IgG2 Protein
While the CD4-IgG2 itself is a potent drug candidate, its design has spurred the invention of several other similar proteins tailor-made to combat specific diseases. One such drug candidate is PRO 140, a monoclonal antibody designed to block the HIV co-receptor CCR5. Another candidate is ibalizumab, an antibody that targets the CD4 receptors but doesn't interfere with their normal functions. These innovative drug designs represent an exciting era of personalized medicine that we are fast-approaching.
The exploration of the CD4-IgG2 protein marks a significant milestone in biotechnological advancements. As we continue investigating its full potential, we can only hope that this protein, along with other novel drug candidates, can truly revolutionize disease treatment and management.
For research use only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products
without prior written approval from Creative BioMart.
For more information on how our products could help advance your project, please contact us.